ArticleMolecular cancer therapeutics2017
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 40 citations in OpenAlex.
- Neddylation: from regulatory mechanisms to clinical implications in cancer.Journal of advanced research · 2026Review
- Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma.Current medicinal chemistry · 2025Review
- Proteogenomic Analysis Identifies Clinically Relevant Subgroups of Collecting Duct Carcinoma.Research (Washington, D.C.) · 2025Article
- NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues.International journal of molecular sciences · 2024Review
- Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.Clinical and experimental medicine · 2024Article
- Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways.Biomarker research · 2024Review
- Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.Neuro-oncology · 2023Article
- Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions.Journal of hematology & oncology · 2023Review
- Targeting neddylation as a novel approach to lung cancer treatment (Review).International journal of oncology · 2023Review
- Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023Article
- The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas.Journal of cancer metastasis and treatment · 2023Article
- Advances in the potential roles of Cullin-RING ligases in regulating autoimmune diseases.Frontiers in immunology · 2023Review
- The Hippo pathway in endometrial cancer: a potential therapeutic target?Frontiers in oncology · 2023Review
- Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library.Genome medicine · 2022Article
- Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.Targeted oncology · 2022Review
- An Integrative Pan-Cancer Analysis Revealing MLN4924 (Pevonedistat) as a Potential Therapeutic Agent Targeting Skp2 in YAP-Driven Cancers.Frontiers in genetics · 2022Article
- Novel and Promising Systemic Treatment Approaches in Mesothelioma.Current treatment options in oncology · 2021Review
- A Review of Pharmacologic Management in the Treatment of Mesothelioma.Current treatment options in oncology · 2021Review
- Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects.Frontiers in oncology · 2021Review
- Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
13 authors at 3 institutions in 2 countries.
Jonathan CooperCell Biology Program and Center for Metastasis Research, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York. fggiancotti@mdanderson.org cooper.jonathan@gene.com.
Qingwen XuDepartment of Cancer Biology and David H. Koch Center for Applied Research of Genitourinary Cancers, University of Texas MD Anderson Cancer Center, Houston, Texas.
Lu ZhouPlymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom.
Milica PavlovicCell Biology Program and Center for Metastasis Research, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Virginia OjedaCell Biology Program and Center for Metastasis Research, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Kamalika MoulickCell Biology Program and Center for Metastasis Research, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Elisa de StanchinaAntitumor Assessment Core Facility, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
John T PoirierThoracic Oncology Service and Druckenmiller Center for Lung Cancer Research, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York.
Marjorie ZaudererThoracic Oncology Service and Druckenmiller Center for Lung Cancer Research, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York.
Charles M RudinThoracic Oncology Service and Druckenmiller Center for Lung Cancer Research, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York.
Matthias A KarajannisDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
C Oliver HanemannPlymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom.
Filippo G GiancottiDepartment of Cancer Biology and David H. Koch Center for Applied Research of Genitourinary Cancers, University of Texas MD Anderson Cancer Center, Houston, Texas. fggiancotti@mdanderson.org cooper.jonathan@gene.com.
Memorial Sloan Kettering Cancer Center · USPeninsula College of Medicine and Dentistry · GBThe University of Texas MD Anderson Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MMechanisms governing metastatic dormancy and reactivationR35CA197566 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GIANCOTTI, FILIPPO G · 2016 to 2022
$6.7MTherapeutic efficacy of the CRL inhibitor MLN4924 in NF2 mutant mesotheliomaR01CA191222 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GIANCOTTI, FILIPPO G, ZAUDERER, MARJORIE G. · 2016 to 2020
$2.5MMechanism of Merlin-mediated contact inhibition and tumor suppression.R01CA152975 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI GIANCOTTI, FILIPPO G · 2010 to 2014
$2.5MExploration of Activity of RAD001 in vivo in Vestibular Schwannomas and MeningiomR01CA164295 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KARAJANNIS, MATTHIAS ANGELOS, ZAGZAG, DAVID · 2012 to 2017
$1.5MCancer Research UK 16401NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA152975NCI NIH HHS R01 CA164295NCI NIH HHS R01 CA191222NCI NIH HHS R35 CA197566
Abstract
Inactivation of
Indexed as
AnimalsCarcinogenesisCell Line, TumorCell ProliferationCyclopentanesHumansLung NeoplasmsMesotheliomaMesothelioma, MalignantMiceMutationNeurofibromin 2OncogenesPhosphatidylinositol 3-KinasesPleural NeoplasmsPyrimidinesCyclopentanesNAE protein, humanNeurofibromin 2pevonedistatPhosphatidylinositol 3-KinasesPyrimidinesTOR Serine-Threonine KinasesUbiquitin-Activating Enzymes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.